Abstract
Alzheimer's disease (AD) is a high-risk and atrophic neurological illness that slowly and gradually destroys brain cells (i.e. neurons). As the most common type of amentia, AD affects 60–65% of all people with amentia and poses major health dangers to middle-aged and elderly people. For classification of AD in the early stage, classification systems and computer-aided diagnostic techniques have been developed. Previously, machine learning approaches were applied to develop diagnostic systems by extracting features from neural images. Currently, deep learning approaches have been used in many real-time medical imaging applications. In this study, two deep neural network techniques, AlexNet and Restnet50, were applied for the classification and recognition of AD. The data used in this study to evaluate and test the proposed model included those from brain magnetic resonance imaging (MRI) images collected from the Kaggle website. A convolutional neural network (CNN) algorithm was applied to classify AD efficiently. CNNs were pre-trained using AlexNet and Restnet50 transfer learning models. The results of this experimentation showed that the proposed method is superior to the existing systems in terms of detection accuracy. The AlexNet model achieved outstanding performance based on five evaluation metrics (accuracy, F1 score, precision, sensitivity, and specificity) for the brain MRI datasets. AlexNet displayed an accuracy of 94.53%, specificity of 98.21%, F1 score of 94.12%, and sensitivity of 100%, outperforming Restnet50. The proposed method can help improve CAD methods for AD in medical investigations.
Highlights
Alzheimer's disease (AD) is a noetic disease that affects the elderly
Neural network techniques are the fundamental basis on which deep learning can depend, which denotes the use of artificial neural networks (ANNs) with different layers
This subsection presents the experimental results of ResNet50 and AlexNet as proposed models for the classification of AD
Summary
Alzheimer's disease (AD) is a noetic disease that affects the elderly. In the early stages of the disease, short-term memory loss is observed; as the disease progresses, behavioural and cognitive functions are lost [3]. Degenerative disorders often appear at the age of ≥60 years, but AD has been diagnosed early in individuals between the ages of 40 and 50 years. One of the goals of neuroscience is to identify biomarkers for early detection of AD and to determine its treatment response. The number of patients with AD is increasing continuously. According to Alzheimer's Disease International (ADI) reports [5], the total number of people with AD was 46.8 million in 2015 [5], which increased to 50 million in 2018 [6]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.